TABLE 1.
Multivariable Cox Regression Analyses in the Multicenter Enfortumab Vedotin Cohort
| Characteristic | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| No. | HR | 95% CI | P | No. | HR | 95% CI | P | |
| NECTIN4 CNV status | <.001 | <.001 | ||||||
| Nonamplified | 80 | — | — | 80 | — | — | ||
| Amplified | 28 | 0.14 | 0.06 to 0.30 | 28 | 0.08 | 0.02 to 0.34 | ||
| Age, years | .25 | .71 | ||||||
| <75 | 86 | — | — | 86 | — | — | ||
| ≥75 | 22 | 0.70 | 0.38 to 1.30 | 22 | 1.16 | 0.54 to 2.47 | ||
| Sex | .28 | .58 | ||||||
| Male | 81 | — | — | 81 | — | — | ||
| Female | 27 | 1.36 | 0.79 to 2.34 | 27 | 0.83 | 0.41 to 1.65 | ||
| Liver metastasis | .31 | .023 | ||||||
| No | 76 | — | — | 76 | — | — | ||
| Yes | 32 | 0.77 | 0.46 to 1.29 | 32 | 2.06 | 1.11 to 3.82 | ||
| ECOG | .090 | <.001 | ||||||
| 0 | 36 | — | — | 36 | — | — | ||
| ≥1 | 72 | 1.53 | 0.92 to 2.55 | 72 | 4.84 | 2.01 to 11.7 | ||
| Hemoglobin, g/dL | .54 | .16 | ||||||
| ≥10 | 104 | — | — | 104 | — | — | ||
| <10 | 4 | 0.71 | 0.23 to 2.19 | 4 | 0.29 | 0.04 to 2.24 | ||
NOTE. Significant P values are highlighted in bold.
Abbreviations: CNV, copy number variation; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.